Skip to main content

2 Result(s)

within Joseph P. Eder Jr Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

    Purpose: BMS-214662 is a novel farnesyltransferase (FT) inhibitor that has shown promising suggestions of single agent activity in patients with advanced solid tumors when administered as...

    Joseph P. Eder Jr, David P. Ryan, Leonard Appleman… in Cancer Chemotherapy and Pharmacology (2006)

  2. No Access

    Article

    A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

    Purpose: 4′-N-Benzoyl-staurosporine (PKC412) is an orally available staurosporine derivative that inhibits protein kinase C. The objectives of this phase I trial were to determine the maximum tolerated dose (MTD...

    Joseph P. Eder Jr, Rocio Garcia-Carbonero, Jeffrey W. Clark… in Investigational New Drugs (2004)